The most dangerous lie in the drug discourse is the word “drug.”
It is a category that lumps together molecules that do not belong in the same sentence. Psilocybin and fentanyl are both “drugs.” LSD and methamphetamine are both “drugs.” This linguistic collapse is not an accident. It is a regulatory convenience, a legacy of prohibition-era classification that has done more to obscure the neurobiology than to clarify it. The consequences have been catastrophic.
This post is about the three classes that are not psychedelics: amphetamines, cocaine, and opiates. They are not consciousness-expanding. They are not neuroplasticity-promoting in the therapeutic sense. They are not teachers. They are dopamine floods and receptor hijackers, and their chronic use produces a contraction of consciousness that is the precise opposite of the psychedelic experience. They belong in hospitals, under clinical supervision, administered by physicians. They do not belong in the culture of self-exploration that the psychedelic renaissance has legitimately revived.
The Neurobiology of the Chasm
The classical psychedelics—psilocybin, LSD, mescaline, DMT—are 5-HT₂A receptor agonists. They work through serotonergic pathways that engage the prefrontal cortex, the visual system, and subcortical regions, producing what one review describes as “broad effects on neural systems”. A recent neuroimaging study comparing LSD, psilocybin, and mescaline to MDMA and d-amphetamine found that psychedelics produced significant increases in meta-state complexity, short-timescale multiscale entropy, and dynamic conditional correlation entropy—distinct patterns that distinguish the psychedelic state from other psychoactive drug effects. The brain under psychedelics becomes more complex, more entropic, more flexible. The brain under stimulants becomes something else entirely.
Cocaine blocks the reuptake of dopamine. Amphetamines stimulate dopamine and norepinephrine release. Opiates agonize mu, delta, and kappa receptors. These are not variations on a theme. They are different operating systems.
The dopaminergic system is the brain’s reward and reinforcement pathway. It is the same system that governs eating, drinking, sleeping, and sex—essential physiological behaviors. When you hijack it with cocaine or amphetamine, you are not opening a window for insight. You are flooding a system that evolved to respond to survival-relevant stimuli with a signal that has no biological referent. The result is reinforcement without satiation, desire without fulfillment, and a progressive downregulation of the very receptors that make ordinary life feel worth living.
The opioid system is the brain’s pain and pleasure pathway. Mu-opioid receptor activation alleviates severe pain, but it also produces reward and respiratory depression—the latter being the main cause of death associated with opioid overdose. The therapeutic window is narrow. The margin between analgesia and asphyxiation is measured in milligrams.
Amphetamines: The Illusion of Productivity
Amphetamine was discovered in 1929 by biochemist Gordon Alles, who was searching for a decongestant to replace ephedrine. He patented the orally active salts in 1932, and the Philadelphia firm Smith, Kline and French marketed it as the Benzedrine Inhaler, a capped tube containing 325 milligrams of oily amphetamine base. It was sold over the counter for nasal congestion. The American Medical Association approved advertising of amphetamine tablets for narcolepsy. By the late 1940s, the pharmacological effects on attention, cognition, emotions, and appetite had been thoroughly explored and were being marketed aggressively.
What followed was the first iatrogenic amphetamine epidemic in the United States, lasting from the 1940s through the 1960s. The epidemic was generated by the pharmaceutical industry and the medical profession as a byproduct of routine commercial drug development and competition. Retrospective epidemiology indicates that the prevalence of nonmedical stimulant use and stimulant dependence or abuse reached nearly the same levels by the early 2000s as at the epidemic’s peak around 1969.
The neurotoxicity is not subtle. Methamphetamine damages the dopaminergic system in all animal species including humans, killing dopamine neurons and reducing dopamine transporter binding sites in human addicts. In vervet monkeys, a single acute dose of amphetamine or methamphetamine produced a 60–70% decrease in striatal dopamine synthesis capacity. The drug does not merely alter function. It destroys structure.
The illusion of amphetamine is productivity. The user feels focused, energetic, capable. What is actually happening is that the brain’s reward system is being driven at gunpoint, and the debt accumulates. The crash is not a side effect. It is the bill.
Clinical use cases. Amphetamines are FDA-approved for two indications: attention-deficit/hyperactivity disorder (ADHD) and narcolepsy, in both adult and pediatric populations (NCBI, 2026). The dextroamphetamine-amphetamine combination is a Schedule II controlled substance precisely because its therapeutic utility is inseparable from its high abuse potential. In ADHD, amphetamines are prescribed alongside psychological, educational, and social interventions to manage distractibility, short attention span, hyperactivity, and impulsivity (NCBI, 2026). In narcolepsy, they are used to manage daytime sleepiness, though the American Academy of Sleep Medicine recommends modafinil and pitolisant as preferred agents (NCBI, 2026). The clinical context is everything: titrated doses, cardiovascular monitoring, regular reassessment. Without that scaffolding, the same molecule that helps a child sit still in a classroom becomes the engine of a destroyed dopaminergic system.
Prescription Amphetamine Analogs: Methylphenidate and the Contested Terrain. Methylphenidate—sold as Ritalin, Concerta, and a dozen other formulations—is not an amphetamine in the strict chemical sense, but it belongs in this conversation because it produces the same functional outcome through a different molecular route. It blocks the reuptake of dopamine and norepinephrine rather than stimulating their release, but the downstream effect on the reward and attention systems is convergent. It is the most commonly prescribed medication for ADHD worldwide, and it is also the most contested.
The clinical use cases are narrow and well-defined. Methylphenidate is FDA-approved for attention-deficit/hyperactivity disorder in children and adults, and for narcolepsy. In ADHD, it is prescribed as part of a comprehensive treatment program that includes psychological, educational, and social interventions—not as a standalone fix. The doses are titrated over weeks, starting low and increasing gradually to achieve maximum benefit with tolerable side effects. The recommended ceiling is 0.7 mg/kg per dose up to three times daily, or a total daily dose of 2.1 mg/kg/day, though clinical practice varies widely. For narcolepsy, it is used to manage excessive daytime sleepiness, though the American Academy of Sleep Medicine now recommends modafinil and pitolisant as preferred first-line agents.
The contested terrain begins with the question of what “efficacy” actually means. The short-term evidence is robust: methylphenidate reduces core ADHD symptoms in children and adolescents with moderate to large effect sizes, and it is first-line pharmacotherapy in every major guideline. But the long-term picture is far murkier. A Cochrane review found that evidence on long-term effects is lacking, and that when methylphenidate is used for longer periods, “any beneficial effects may be diminished or offset by an increase in the risk of harm”. A subgroup analysis comparing short-term trials of six months or less to a single long-term trial of more than six months found that the treatment effect for teacher-rated ADHD symptoms decreased over time. The same review found that only eight of 212 included trials measured quality of life, and the external assessors observed no beneficial effects of methylphenidate on quality of life. The 2019 and 2021 WHO Expert Committee declined to grant methylphenidate essential medicines status, concluding that “evidence for efficacy is inconclusive” and citing uncertainties in the benefit-harm profile.
The cognitive enhancement question is even more contested. A meta-analysis of 148 studies found that methylphenidate improved academic productivity but not accuracy—users completed more work but did not make fewer errors. Other research suggests that improved attention and vigilance may come at the cost of long-term memory, executive functions, and creative thinking. The presumption that stimulants improve cognition in healthy individuals is increasingly challenged; the more defensible claim is that they provide a volitional advantage—treating apathy, improving task enjoyment, and making users more inclined to engage in high-effort, high-reward tasks.
The adverse effects are well-documented. Sleep disturbances, anorexia, nervousness, and, in rare cases, cardiac events have been reported. The FDA labeling warns of sudden death, stroke, and myocardial infarction in adults taking stimulants at usual doses for ADHD. Blood pressure increases of 2–4 mmHg and heart rate increases of 3–6 bpm are typical. Psychiatric adverse reactions include psychosis, mania, and aggression. In pediatric populations, growth suppression is a monitored concern. And there is a significant lack of long-term data on therapeutic benefits and adverse effects beyond 30 weeks of treatment.
The pattern is consistent with everything else in this post. Methylphenidate is a legitimate medication for a legitimate diagnosis. It works in the short term. It is prescribed under clinical supervision, with monitoring, at titrated doses. But the long-term outcomes are contested, the enhancement claims are overstated, and the adverse effects are real. The difference between methylphenidate and the other stimulants in this post is not the mechanism or the risk profile. It is the regulatory scaffolding that surrounds it—the clinical context, the monitoring, the dose ceilings, the recognition that the molecule is a tool and not a lifestyle. That scaffolding is the only thing separating prescription from predation.
Cocaine: The Cardiovascular Catastrophe
Cocaine is a powerful sympathomimetic agent and a local anesthetic. It blocks the presynaptic reuptake of catecholamines, resulting in marked hormonal increases at postsynaptic receptor sites. These effects lower the threshold for coronary vasoconstriction and vasospasm, myocardial ischemia, and infarction. The drug’s multiple pharmacologic and electrophysiologic cardiovascular actions can promote arrhythmias, myocarditis, and cardiomyopathy, as well as unmasking subclinical diseases.
The cardiovascular effects are dose-dependent. Early stages of toxicity induce heart rate and blood pressure elevations of 10% to 25% of baseline. Advanced stages show further elevations. Cocaine potentiates acute sympathetic effects on the cardiovascular system in ways that can be lethal at doses that produce no warning symptoms. Circulating catecholamine concentrations can be raised as much as fivefold.
What distinguishes cocaine from the psychedelics is not merely the mechanism. It is the direction of the effect. Psilocybin and LSD produce what researchers describe as consciousness-expanding states. Opiates, alcohol, cocaine, and amphetamines produce the opposite: addicted, fixated, contracted states of consciousness. The psychedelic experience is centrifugal—it expands the self outward toward connection and meaning. The stimulant experience is centripetal—it contracts the self inward toward craving and compulsion.
But the cardiovascular catastrophe is only half the story. The other half is the motivational hijack. Cocaine does not merely flood the brain’s reward system with dopamine. It blocks the dopamine transporter—the protein responsible for clearing dopamine from the synapse—so that the neurotransmitter accumulates and the signal persists far beyond its natural duration. The result is not pleasure in the ordinary sense. It is a pharmacologically induced certainty that the most important thing in the world is more cocaine. The mesolimbic pathway, which evolved to motivate pursuit of food, sex, and social connection, is commandeered to motivate pursuit of a white powder. The craving that follows is not a desire for a substance. It is a usurpation of the motivational system itself. The user does not want cocaine the way they want food. They want it the way they want air. This is why cocaine is so notoriously difficult to quit even when the user knows, with complete clarity, that the drug is destroying their heart, their finances, and their relationships. The knowing is irrelevant. The motivational pathway has been reprogrammed, and it does not take instructions from the prefrontal cortex.
Whatever you decide to do, try to avoid cocaine.
Clinical use cases. Cocaine is not FDA-approved, but it is permitted for a single narrow indication: topical anesthesia of the mucous membranes of the oral, laryngeal, and nasal cavities (NCBI, 2026). Its vasoconstrictive properties also make it useful for the temporary treatment of epistaxis before cauterization or packing, which is considered off-label use (NCBI, 2026). The American Academy of Otolaryngology-Head and Neck Surgery considers cocaine a valuable anesthetic and vasoconstricting agent when used as part of physician-directed treatment, noting that no other single drug combines its anesthetic and vasoconstricting properties (AAO-HNS, 2014). In modern practice, it is used as a topical intranasal anesthetic for sinus surgery or, less commonly, for awake intubation in a 4% solution (Oxford Academic, 2024). The distinction between this and recreational use is not moral. It is the difference between a controlled 4% topical solution applied to a mucous membrane by a surgeon and a molecule entering the systemic circulation at doses that can precipitate myocardial infarction.
Opiates: The Respiratory Cliff
Opioids share a common pharmacological property: they act as agonists at mu opioid receptors, producing similar behavioral effects including abuse-related, pain-relieving, dependence-producing, and respiratory-depressant effects. The receptor that mediates the analgesia also mediates the reward and the respiratory depression. They cannot be separated by the pharmacology of the drug itself.
The opioid crisis is not a natural disaster. It is a man-made catastrophe. In 2026, a $7.4 billion settlement with Purdue Pharma and the Sackler family became legally effective, resolving litigation for aggressively marketing opioids in the United States and fueling the largest drug crisis in the country’s history. The settlement permanently bars the Sacklers from selling opioids in the U.S. and delivers funds for addiction treatment, prevention, and recovery. Purdue Pharma shut down and ceased operations as part of the bankruptcy plan.
The lesson is not that opioids are evil. It is that opioids are powerful, and power without supervision is predation. The clinical use of opioids for severe pain is legitimate and necessary. The pharmaceutical marketing of opioids as safe for chronic non-cancer pain was fraud, and the consequences are measured in hundreds of thousands of deaths.
Clinical use cases. Morphine sulfate is FDA-approved for moderate-to-severe pain, whether acute or chronic (NCBI, 2025). Clinical situations that significantly benefit from opioid analgesia include musculoskeletal pain, abdominal pain, chest pain, arthritis, and headaches when patients fail to respond to first- and second-line agents (NCBI, 2025). In hospital settings, patient-controlled analgesia provides a safe and flexible method for administering opioids when pain is severe or oral analgesics are inadequate; the physician controls the bolus amount, interval, and maximum cumulative dose over a predetermined period (MSD Manual, 2025). Fentanyl is available in transmucosal and intranasal formulations for breakthrough pain in cancer patients, and buprenorphine comes in buccal and sublingual formulations for chronic pain (MSD Manual, 2025). Methadone is used for heroin withdrawal and long-term maintenance treatment of opioid use disorder (MSD Manual, 2025). The clinical context is not optional. It is the difference between analgesia and asphyxiation.
Prescription Opiates: The Narrow Indications. The clinical use cases for prescription opioids are not a matter of physician discretion. They are specified in FDA labeling, constrained by CDC guidelines, and limited to a small number of clearly defined situations.
The core indication is pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. That language appears verbatim on the labels for oxycodone, hydrocodone-acetaminophen, and every other prescription opioid in the class. The qualifier is doing the work. “Severe enough to require an opioid” excludes mild pain, mild-to-moderate pain, and any pain for which NSAIDs, acetaminophen, or non-pharmacological interventions have not been adequately tried.
The validated clinical situations fall into three categories.
Acute severe pain. For acute pain, pure agonists with short duration of action—immediate-release formulations—are used at the lowest effective dose for the shortest period. The CDC guideline limits opioids for acute pain to three to five days, noting they are rarely necessary beyond seven days. This covers post-surgical pain, severe trauma, and acute exacerbations of painful conditions where non-opioid therapies have failed.
Cancer pain. Opioids should generally not be withheld during the treatment of cancer pain; in these cases, adverse effects can be prevented or managed and dependence is less of a concern. Fentanyl transmucosal and buccal formulations are specifically indicated for breakthrough cancer pain in patients already receiving and tolerant to around-the-clock opioid therapy for underlying persistent cancer pain. Pure agonists such as codeine, fentanyl, oxycodone, and oxymorphone are the most commonly used medications in cancer pain management, with short half-life agonists preferred.
Chronic non-cancer pain, under narrow conditions. For chronic non-cancer pain, guidelines emphasize patient selection: obvious organic cause of the persistent pain, low risk of psychosocial factors, pain refractory to non-opioid therapies, and good adherence to medication. The upper limit is 90 morphine milligram equivalents per day, with a target duration of three to six months. The CDC guideline advises avoiding increases to 90 MME or more, and notes there is no good evidence for long-term opioid use for sports injuries, fibromyalgia, or low-back pain—the indications for which they are most commonly prescribed.
The specific agents and their roles are standardized. Morphine sulfate is indicated for moderate-to-severe acute or chronic pain. Oxycodone and hydrocodone are indicated for pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate, with the lowest effective dose for the shortest duration. Methadone is used for heroin withdrawal and long-term maintenance treatment of opioid use disorder, as well as for severe pain. Buprenorphine is available in buccal and sublingual formulations for chronic pain and is also used for opioid use disorder treatment.
The pattern is consistent. Prescription opioids have legitimate, life-improving, and sometimes life-saving applications. Those applications are narrow, monitored, and bounded by dose ceilings and duration limits. The same molecule that relieves the pain of a post-surgical patient or a cancer patient is the molecule that destroyed entire communities when it was marketed as safe for chronic non-cancer pain without those constraints. The clinical context is not a formality. It is the difference between medicine and catastrophe.
What Clinical Supervision Means
The phrase “inside hospital walls” is not a metaphor. It is a clinical standard. Opioid agonist treatment—methadone, buprenorphine, slow-release oral morphine—is standard of care for opioid use disorder and is life-saving. Supervised consumption sites provide sterile equipment, emergency intervention for overdoses, counseling, primary medical care, overdose awareness and naloxone training, and referral to treatment services. Injectable opioid agonist treatment, approved in Canada following the NAOMI trial, provides pharmaceutical-grade hydromorphone to patients who have not responded to other forms of treatment.
These are not harm reduction measures that enable addiction. They are medical interventions that keep people alive long enough to recover. The distinction between supervised medical use and unsupervised recreational use is not a moral distinction. It is a survival distinction.
The same logic applies to amphetamines and cocaine. Stimulant medications for ADHD are prescribed at doses that have been titrated over months, monitored for cardiovascular effects, and adjusted for individual response. Cocaine has no accepted medical use in modern practice, but its local anesthetic properties—which are structurally distinct from its addictive properties—are the basis for the development of safer synthetic analogs. The molecule is a tool. The tool belongs in trained hands.
The Psychedelic Contrast
The psychedelics are not in this category. Psilocybin, LSD, ayahuasca, and mescaline have shown promising results in clinical trials for PTSD, major depressive disorder, and anxiety disorders, with moderate to large effect sizes. A living systematic review with meta-analysis found that MDMA and serotonergic psychedelics were not associated with higher risk of all-cause discontinuation compared to control, which is a clinical way of saying they do not produce the compulsive use pattern that defines addiction.
This does not make them safe. It makes them different. The psychedelic experience is not a dopamine flood. It is not a receptor hijack. It is a temporary reconfiguration of the brain’s default mode network, a window of heightened metaplasticity that can be used therapeutically if it is properly framed and integrated. The risk profile is psychological, not cardiovascular. The dependency profile is negligible, not inevitable.
The clinical consensus for psychedelics is the same as the clinical consensus for every other powerful molecule: supervised administration, trained therapist, controlled setting, preparation and integration. The difference is that the psychedelics are being studied for their therapeutic potential. Amphetamines, cocaine, and opiates are being studied for their mechanisms of harm, and the findings are consistent across every study: they destroy the system they activate.
The Category Error
The war on drugs failed because it treated all substances as equivalent. It conflated the teacher with the predator. It locked up the molecule that opens the mind alongside the molecule that closes it. The result was a regulatory regime that had no relationship to neurobiology and a public discourse that had no relationship to evidence.
The correction is not to legalize everything. It is to differentiate. Amphetamines, cocaine, and opiates are not psychedelics. They are not consciousness-expanding. They are not neuroplasticity-promoting in the therapeutic sense. They are dopamine floods and receptor hijackers, and their chronic use produces a contraction of consciousness that is the precise opposite of the psychedelic experience. They belong in hospitals, under clinical supervision, administered by physicians who understand their pharmacology and monitor their effects.
The psychedelics belong in clinics, under clinical supervision, administered by therapists who understand their psychology and guide their integration. The two domains are separate. The molecules are different. The outcomes are different. The culture should be different too.
Alcohol belongs in this class of chemicals. Therefore, alcohol use as well should be culturally moderated. The recommendation is to promote a drinking culture that avoids binge drinking, limiting alcohol consumption to 4 to 6 standard restaurant servings per sitting during structured meals.